CYBN
Cybin·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CYBN
Cybin Inc.
A biopharmaceutical company that developing psychedelic therapeutics for psychiatric disorders
100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9
--
Cybin Inc., was founded in 2019 in Ontario, Canada. The company operates in Canada, the United States, the United Kingdom and Ireland. The company focuses on developing psychedelics into therapies by designing patented drug discovery platforms, innovative drug delivery systems, novel formulation methods and treatment options for mental health disorders.
Earnings Call
Q2/2026
Estimate EPS-0.948442
Actual EPS-1.39
Estimate Revenue--
Actual Revenue--
Cybin's 2026 Q2 Earnings Call: Contradictions Emerge on Payer Engagement, FDA Guidance, and Dosing Strategies for CYB003/CYB004
Nov 13,2025 03:56
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CYBN has released its 2026 Q2 earnings. EPS was reported at -1.39, versus the expected -0.94844184554007, missing expectations. The chart below visualizes how CYBN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
